Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features
- PMID: 40579588
- PMCID: PMC12377259
- DOI: 10.1038/s43018-025-00987-2
Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features
Abstract
Developmental origins and their associations with lineage plasticity and treatment response in B-cell progenitor acute lymphoblastic leukemia (B-ALL) are mostly unexplored. Here, we integrated single-cell transcriptome sequencing (scRNA-seq) of 89 B-ALL samples with a single-cell atlas of normal human B cell development incorporating functional and molecular assays. We observed subtype- and sample-dependent correlation with normal developmental stage, with intra-subtype and intra-patient heterogeneity. We show that subtypes prone to shift from the B-lineage (for example BCR::ABL1, KMT2A-R and DUX4-R B-ALL) are enriched for multipotent progenitors and show this developmental stage exhibits CEBPA activation and retains myeloid potential, providing a mechanistic explanation for this clinical observation. We developed a 'multipotency score' most enriched in subtypes exhibiting lineage plasticity that was independently associated with inferior survival. Thus, multipotent B-ALL states reflect the early progenitor origins of a subset of patients with B-ALL and may be relevant for understanding lineage shifting following conventional chemotherapy or immunotherapies.
© 2025. The Author(s), under exclusive licence to Springer Nature America, Inc.
Conflict of interest statement
Competing interests: I.I. reports consultation honoraria from Arima and travel expenses reimbursed by Mission Bio and Takara for invited talks. C.G.M. received research funding from AbbVie and Pfizer, honoraria from Amgen and Illumina, and royalty payments from Cyrus. He is on an advisory board for Illumina. J.E.D. received research funding from BMS/Celgene and intellectual property licenses from Pfizer/Trillium Therapeutics. A.S.A. reported advisory board membership for Nkarta, Pfizer, Novartis and Jazz Pharmaceuticals; honoraria from KSA, PER, MD Education, ALF Medscape/Global Activity, Web med, Onc live AML Geronimo; steering committee membership for Glycomimetics; and royalty payments from Springer. The other authors declare no competing interests.
Update of
-
SINGLE CELL DISSECTION OF DEVELOPMENTAL ORIGINS AND TRANSCRIPTIONAL HETEROGENEITY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA.bioRxiv [Preprint]. 2023 Dec 9:2023.12.04.569954. doi: 10.1101/2023.12.04.569954. bioRxiv. 2023. Update in: Nat Cancer. 2025 Jul;6(7):1242-1262. doi: 10.1038/s43018-025-00987-2. PMID: 38106088 Free PMC article. Updated. Preprint.
References
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
